Performance & Impact
Hangaia te 膩 mua
Create the future
皇家华人 is the largest R&D company of its kind in Australasia. We鈥檝e invested in over 75 companies and licensed more than 540 patent families. We鈥檝e also delivered great community impact.
皇家华人 by the Numbers
8
new companies launched in 2023
27
technologies licensed in 2023
$41m
鈥� Fair value of the University of Auckland Inventors鈥� Fund at the end of 2023
28,592
Covid-19 vaccinator course completions through IMAC since 2021
36,659
鈥� Clinical queries answered on IMAC鈥檚 0800 IMMUNE phone line in 2023
6,755
people engaging with online courses through Wh膩raurau in 2023
5,366
people attending training and workshop courses through Wh膩raurau in 2023
3,900
educators received professional training and development through Tui Tuia | Learning Circle in 2023
4,700
MRI scans performed by CAMRI in 2023
4000+
鈥� Clinical staff in 20 hospitals trained in acute care simulations designed by NetworkZ in the past 8 years
Community Impact
Supporting Covid-19 vaccination
The (IMAC) plays a significant role in educating the country鈥檚 immunisation workforce. More than 5000 IMAC courses were completed by vaccinators across the motu in 2023. IMAC also advised healthcare staff through its 0800 phone line, answering more than 36,000 calls during the year. IMAC also provided expert advice to the government, and responded to continuous media queries.
Understanding wh膩nau experiences
is the largest longitudinal study following the lives of more than 6,000 children, including some 1,200 tamariki M膩ori, since their pregnant mothers volunteered for the study in 2009. It offers evidence and insights into child and youth health and wellbeing in New Zealand for policymakers, researchers, community advocates, and other stakeholders.
Investment Impact
Better optical communications
Quantifi Photonics, a University of Auckland spin-out, manufactures equipment for photonics testing and measurement in areas such as optical communications. It in Series C funding to accelerate the development of test solutions for datacom and telecom equipment manufacturers. It also , giving it research and manufacturing facilities in Thailand.
Diagnosing gut disorders
Alimetry is an Auckland based MedTech company that develops advanced wearable medical solutions that improve gastrointestinal care. Founded in 2019, based on a decade of groundbreaking science and engineering out of Waipapa Taumata Rau, the University of Auckland, Alimetry is striving to develop solutions that are more effective, easier on patients, and more efficient for healthcare providers. In 2022, Alimetry received FDA approval in the US for its flagship Gastric Alimetry device, a non-invasive tool to diagnose disorders of the upper gut, and has raised $16.3 million in Series A funding.
Check out our 2022 annual review
Learn what we achieved in advancing and investing in research and delivering services and projects with community impact.